Results of Study on Trisynex Reported at Two Scientific Conferences Demonstrate

-- 92% Improvement In Lowering Body Fat

-- 62% Improvement In Reducing Waist Circumference



May 22, 2007, 01:00 ET from Imagenetix, Inc.

    SAN DIEGO, May 22 /PRNewswire-FirstCall/ -- Imagenetix, Inc. (OTC
 Bulletin Board: IAGX), announced today that results from the recently
 completed study at the University of Connecticut on its patented body fat
 reduction ingredient, Trisynex, were presented at two scientific
 conferences.
     "We are extremely pleased with the results of this study validating the
 effectiveness of Trisynex in fat loss and body shaping," stated William P.
 Spencer, President of Imagenetix. "We are most excited as Trisynex is just
 beginning to be made available to consumers, on a global basis."
     Dr. Robert Hesslink, Director, Research & Development at Imagenetix,
 presented data at the Slimming Ingredient 2007 conference in Berlin,
 Germany. Dr. Hesslink reviewed the improvements in body composition in
 subjects consuming Trisynex. Subjects consuming Trisynex experienced a 92%
 improvement over placebo in lowering body fat and a 62% improvement in
 reducing waist circumference.
     Dr. William Kraemer and staff from the University of Connecticut
 presented significant clinical data on Trisynex at the Experimental Biology
 conference in Washington, DC. Experimental Biology is the premiere
 international scientific conference in the fields of physiology, nutrition,
 molecular biology and genetics.
     The University of Connecticut presented the Trisynex results on the
 serum adipocytokines and body composition. Subjects consuming Trisynex
 capsules had a significant reduction in serum leptin and a significant
 increase in serum adiponectin. These adipocyte hormones are integral
 biomarkers for healthy body fat storage and utilization.
     The reduced serum leptin reflects the lower body fat and waist
 circumference found in the female subjects. Leptin has been shown to
 regulate the storage of excess calories and its lowering is vital for
 reducing body fat, reduction of waist circumference, and the overall
 management of obesity.
     The elevation in serum adiponectin elicited by the consumption of
 Trisynex is very exciting. Adiponectin has been shown to regulate glucose
 regulation and balance. In addition, adiponectin is thought to increase fat
 oxidation within skeletal muscle, which may serve to increase daily caloric
 expenditure.
     About Imagenetix
     Based in San Diego, California, Imagenetix, (OTC Bulletin Board:   IAGX)
 is an innovator of scientifically tested, natural-based, proprietary
 bioceutical products developed to enhance human health on a global basis.
 Imagenetix develops, formulates and private-labels propriety
 over-the-counter topical creams, skincare products and nutritional
 supplements to be marketed globally through multiple channels of
 distribution. In addition, the company develops patentable compounds for
 entering into licensing agreements with pharmaceutical partners. Imagenetix
 is the creator of Inflame Away(TM)- Celadrin(R), which has been clinically
 tested to relieve osteoarthritis pain and significantly improve joint
 health. For more information, please visit, http://www.imagenetix.net.
     This document contains forward-looking statements within the meaning of
 Section 27A of the Securities Act of 1933, as amended, and Section 21E of
 the Securities Exchange Act of 1934, as amended. Such statements are
 subject to risks and uncertainties that could cause actual results to vary
 materially from those projected in the forward-looking statements. The
 company may experience significant fluctuations in future operating results
 due to a number of economic, competitive, and other factors, including,
 among other things, the size and timing of customer contracts, new or
 increased competition, changes in market demand, and seasonality of
 purchases of the company's products and services. These factors and others
 could cause operating results to vary significantly from those in prior
 periods and those projected in forward-looking statements. Additional
 information with respect to these and other factors, which could materially
 affect the company and its operations, are included in certain forms the
 company has filed and will periodically file with the Securities Exchange
 Commission.
 
 

SOURCE Imagenetix, Inc.
    SAN DIEGO, May 22 /PRNewswire-FirstCall/ -- Imagenetix, Inc. (OTC
 Bulletin Board: IAGX), announced today that results from the recently
 completed study at the University of Connecticut on its patented body fat
 reduction ingredient, Trisynex, were presented at two scientific
 conferences.
     "We are extremely pleased with the results of this study validating the
 effectiveness of Trisynex in fat loss and body shaping," stated William P.
 Spencer, President of Imagenetix. "We are most excited as Trisynex is just
 beginning to be made available to consumers, on a global basis."
     Dr. Robert Hesslink, Director, Research & Development at Imagenetix,
 presented data at the Slimming Ingredient 2007 conference in Berlin,
 Germany. Dr. Hesslink reviewed the improvements in body composition in
 subjects consuming Trisynex. Subjects consuming Trisynex experienced a 92%
 improvement over placebo in lowering body fat and a 62% improvement in
 reducing waist circumference.
     Dr. William Kraemer and staff from the University of Connecticut
 presented significant clinical data on Trisynex at the Experimental Biology
 conference in Washington, DC. Experimental Biology is the premiere
 international scientific conference in the fields of physiology, nutrition,
 molecular biology and genetics.
     The University of Connecticut presented the Trisynex results on the
 serum adipocytokines and body composition. Subjects consuming Trisynex
 capsules had a significant reduction in serum leptin and a significant
 increase in serum adiponectin. These adipocyte hormones are integral
 biomarkers for healthy body fat storage and utilization.
     The reduced serum leptin reflects the lower body fat and waist
 circumference found in the female subjects. Leptin has been shown to
 regulate the storage of excess calories and its lowering is vital for
 reducing body fat, reduction of waist circumference, and the overall
 management of obesity.
     The elevation in serum adiponectin elicited by the consumption of
 Trisynex is very exciting. Adiponectin has been shown to regulate glucose
 regulation and balance. In addition, adiponectin is thought to increase fat
 oxidation within skeletal muscle, which may serve to increase daily caloric
 expenditure.
     About Imagenetix
     Based in San Diego, California, Imagenetix, (OTC Bulletin Board:   IAGX)
 is an innovator of scientifically tested, natural-based, proprietary
 bioceutical products developed to enhance human health on a global basis.
 Imagenetix develops, formulates and private-labels propriety
 over-the-counter topical creams, skincare products and nutritional
 supplements to be marketed globally through multiple channels of
 distribution. In addition, the company develops patentable compounds for
 entering into licensing agreements with pharmaceutical partners. Imagenetix
 is the creator of Inflame Away(TM)- Celadrin(R), which has been clinically
 tested to relieve osteoarthritis pain and significantly improve joint
 health. For more information, please visit, http://www.imagenetix.net.
     This document contains forward-looking statements within the meaning of
 Section 27A of the Securities Act of 1933, as amended, and Section 21E of
 the Securities Exchange Act of 1934, as amended. Such statements are
 subject to risks and uncertainties that could cause actual results to vary
 materially from those projected in the forward-looking statements. The
 company may experience significant fluctuations in future operating results
 due to a number of economic, competitive, and other factors, including,
 among other things, the size and timing of customer contracts, new or
 increased competition, changes in market demand, and seasonality of
 purchases of the company's products and services. These factors and others
 could cause operating results to vary significantly from those in prior
 periods and those projected in forward-looking statements. Additional
 information with respect to these and other factors, which could materially
 affect the company and its operations, are included in certain forms the
 company has filed and will periodically file with the Securities Exchange
 Commission.
 
 SOURCE Imagenetix, Inc.